Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mircera Reviewers Turned To Top-Level FDA Briefing With CRP Concerns

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Unlike trials of other ESAs, Roche’s Mircera studies excluded patients with elevated levels of C-reactive protein, a marker for inflammation. In a move reflective of growing use of interdisciplinary and cross-division expertise within FDA, the review division sought center-level “regulatory briefing” to determine if CRP screening produced a database that was not characteristic of the market. The briefing found the rate of exclusion due to CRP screening insufficient to delay approval of Mircera

You may also be interested in...



Cimzia Met "Minimum Necessary" CDER Standard With CBER-Advised Trials

Insufficient clinical evidence for one aspect of Cimzia’s Crohn’s disease indication came close to derailing FDA’s review of the UCB biologic, but approval was salvaged by FDA’s interest in maintaining consistency between its drugs and biologics centers in agreements made with sponsors during development.

Mircera Review Provided FDA With Forum To Suggest Ideal ESA Studies

With FDA’s review of Roche’s Mircera BLA, the agency went beyond the normal evaluation leading to approval of the drug; it seized the opportunity to weigh in on the proper development of erythropoiesis-stimulating agents.

Relistor Review Offers Glimpse Into FDA’s Evolving Approach To QT Studies

FDA’s review of Wyeth and Progenics’ Relistor (methylnaltrexone) illustrates the agency’s efforts to improve its review of the "thorough QT studies" that FDA requires for all new chemical entities.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS003928

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel